Science Against SARS-CoV-2 Virtual Event Series

New immunotherapies are generating unprecedented clinical response. However, immune activation by I/O agents can also cause notable and potentially fatal clinical toxicity, such as cytokine storms, which is not observed in preclinical studies. Immuno-safety has therefore become a major clinical concern, which needs to be sufficiently addressed in early preclinical drug development.

For every cell in your body, there’s another tiny single-celled creature that also calls your body home. Far from being germs, we should eradicate, these ancient friends allow us to digest food, breathe air, and fight off disease. They were here long before us and will undoubtedly remain long after we’re gone. They are our microbiome, and after eons of cohabitation, we are finally getting to know one another better. Of course, we aren’t always the best of neighbors. Autoimmune diseases, allergies, depression, and Alzheimer’s may be diseases of an unhappy microbiome.

The ability to interpret data is crucial to advancing cell and gene therapy research. But raw data is rarely useful when it comes to gleaning insights.

FFPE tissue samples with a low abundance of nucleic acid continue to present a challenge for cancer genomics. Such samples frequently fail to produce sufficient DNA or RNA for downstream analyses, which can impact patient care or reduce the statistical power of a study.